The blood-brain barrier (BBB) represents the most significant obstacle to delivering therapeutics for Alzheimer's disease, Parkinson's disease, ALS, and FTD. This specialized interface of brain endothelial cells restricts the passage of ~98% of small molecule drugs and virtually all biologics, necessitating innovative technologies to enable effective CNS drug delivery.
BBB crossing is critical for delivering tau-targeting antibodies, alpha-synuclein-targeting therapies, amyloid-beta-targeting biologics, and TDP-43 modulators to the brain. The neuroinflammation driven by microglial activation in Alzheimer's disease is exacerbated by impaired blood-brain barrier function. Similarly, Parkinson's disease shows early BBB disruption in the substantia nigra, complicating therapeutic delivery. In ALS, the BBB breakdown enables peripheral immune infiltration that accelerates motor neuron degeneration. The APOE gene, particularly the ε4 allele, is associated with impaired BBB integrity in Alzheimer's disease, creating additional challenges for therapeutic delivery. Targeting the neurovascular unit may restore BBB function while enabling drug delivery.
¶ Structure and Function
- Tight junctions: Formed by claudins, occludin, and junctional adhesion molecules
- Endothelial cells: Specialized cells with low pinocytic activity
- Pericytes: Contractile cells regulating capillary diameter
- Astrocyte end-feet: Provide signaling support for barrier function
- Passive diffusion: Only small, lipophilic molecules (<400 Da) cross efficiently
- Carrier-mediated transport: Endogenous transporters for glucose, amino acids
- Receptor-mediated transcytosis: For large molecules like transferrin, insulin
- Absorptive-mediated transcytosis: For cationic proteins
- Mechanism: Low-density lipoprotein receptor-related protein 1 for delivery to basal ganglia neurons
- Advantages: High expression on BBB endothelium
- Applications: Peptide and antibody delivery targeting tau pathology
¶ Nanoparticle Encapsulation
- Types: Liposomes, polymeric nanoparticles, dendrimers for delivery of antibodies to the brain
- Advantages: Protects cargo, enables targeted delivery via autophagy pathways
- Challenge: Manufacturing and reproducibility for clinical use in ALS
¶ Virus-like Particles
- Platform: Non-replicating viral particles
- Advantages: Can be engineered for CNS targeting of hippocampal neurons
- Challenge: Manufacturing scale-up for clinical trials
- Target: TDP-43 pathology in ALS
- Enables biologic delivery: Makes antibodies, enzymes, gene therapies deliverable
- Reduced invasive procedures: Non-surgical delivery possible
- Improved safety: Targeted delivery reduces off-target effects
- Dose reduction: More efficient delivery lowers required doses
- Expanded therapeutic options: Enables new drug modalities
- Technical complexity: Engineering reliable crossing mechanisms that maintain blood-brain barrier integrity while enabling drug delivery to neurons
- Reproducibility: Manufacturing consistent products for tau and alpha-synuclein targeting in Alzheimer's and Parkinson's
- Safety concerns: Potential for off-target delivery triggering neuroinflammation via microglial activation
- Regulatory hurdles: Novel platforms require extensive characterization for amyloid-beta immunotherapies
- Distribution: Achieving uniform brain coverage to hippocampus, basal ganglia, and substantia nigra
- Redosing: Pre-existing antibodies may block repeat dosing in immunotherapy approaches
- Age-related changes: Aging reduces BBB integrity while also impairing transcytosis mechanisms
- Disease-specific alterations: Microvascular changes in vascular dementia differ from Alzheimer's disease
| Technology |
Company |
Application |
Stage |
| Brain Shuttle |
Roche |
Antibodies |
Phase I/II |
| Transport Vehicle |
Denali |
Enzymes |
Preclinical |
| Focused Ultrasound |
Insightec |
AAV, Antibodies |
Phase II |
| RMT Platform |
JCR |
Enzyme replacement |
Approved (Japan) |
- 20+ BBB-crossing programs in clinical development
- Focused ultrasound most clinically advanced
- Antibody-based platforms showing promise
- Gene therapy delivery emerging as key application
- Roche: Brain Shuttle technology
- Genentech: RMT antibody platforms
- Biogen: Multiple BBB technologies
- Eli Lilly: Brain delivery partnerships
- Denali Therapeutics: Transport Vehicle platform
- J-Brain Pharma: J-Brain Cargo technology
- Verve Therapeutics: LRP1-directed delivery
- Cyclo Therapeutics: Cyclodextrin platform
- Insightec: Focused ultrasound device
- CarThera: Ultrasound-based delivery
- Exosome Sciences: Exosome platform
- University of California: Focused ultrasound
- University of Cambridge: Novel RMT targets
- NIH: Fundamental BBB transport research
| Method |
Cargo Size |
Invasiveness |
Clinical Status |
Re-dosing |
| RMT antibodies |
<150 kDa |
Low |
Phase I/II |
Challenged |
| Brain Shuttle |
<150 kDa |
Low |
Phase I/II |
Possible |
| Focused ultrasound |
Any |
Moderate |
Phase II |
Possible |
| Intrathecal |
Large |
High |
Approved |
Possible |
| Nanoparticles |
Variable |
Low |
Preclinical |
Possible |
- Bispecific antibodies: Targeting BBB transporter plus therapeutic target
- Novel AAV capsids: Engineered for BBB crossing
- Trojan horse proteins: Engineered for CNS delivery
- Membrane-active peptides: Enhanced cellular entry
- Focused ultrasound with AAV delivery
- Brain shuttle plus novel biologics
- Chemical modification plus nanoparticle delivery
- Increased understanding enabling faster development
- Platform approaches reducing development time
- Biomarkers for delivery efficiency